NASDAQ:CMRX Chimerix (CMRX) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free CMRX Stock Alerts $0.90 +0.01 (+1.12%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.88▼$0.9150-Day Range$0.88▼$1.2652-Week Range$0.88▼$1.57Volume225,998 shsAverage Volume391,151 shsMarket Capitalization$80.28 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Chimerix alerts: Email Address Chimerix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside789.0% Upside$8.00 Price TargetShort InterestHealthy1.66% of Float Sold ShortDividend StrengthN/ASustainability-2.49Upright™ Environmental ScoreNews Sentiment-0.10Based on 4 Articles This WeekInsider TradingSelling Shares$6,598 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.77) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.86 out of 5 starsMedical Sector179th out of 908 stocksPharmaceutical Preparations Industry68th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChimerix has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.66% of the float of Chimerix has been sold short.Short Interest Ratio / Days to CoverChimerix has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chimerix has recently increased by 6.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChimerix has received a 58.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pox medications" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Chimerix is -2.49. Previous Next 1.1 News and Social Media Coverage News SentimentChimerix has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Chimerix this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Chimerix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,598.00 in company stock.Percentage Held by InsidersOnly 10.00% of the stock of Chimerix is held by insiders.Percentage Held by Institutions45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chimerix are expected to decrease in the coming year, from ($0.77) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChimerix has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Chimerix Stock (NASDAQ:CMRX)Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Read More CMRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMRX Stock News HeadlinesApril 24, 2024 | globenewswire.comChimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024April 24, 2024 | americanbankingnews.comChimerix (NASDAQ:CMRX) Shares Pass Below 200-Day Moving Average of $1.00April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 16, 2024 | globenewswire.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 16, 2024 | americanbankingnews.comChimerix (NASDAQ:CMRX) Stock Price Crosses Below 200 Day Moving Average of $1.00April 15, 2024 | finance.yahoo.comWe Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth CarefullyMarch 16, 2024 | finance.yahoo.comCMRX Apr 2024 2.000 callMarch 16, 2024 | finance.yahoo.comCMRX Apr 2024 1.000 putApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. March 5, 2024 | finance.yahoo.comChimerix Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 2, 2024 | seekingalpha.comChimerix, Inc. (CMRX) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | seekingalpha.comChimerix: Tackling A Strong Unmet Need With Promising DataMarch 1, 2024 | finance.yahoo.comChimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Chimerix Amid Progress in Dordaviprone’s Phase III Study and Strong Financial OutlookFebruary 29, 2024 | finanznachrichten.deChimerix, Inc.: Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational UpdateFebruary 29, 2024 | finance.yahoo.comChimerix Inc Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comChimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational UpdateFebruary 28, 2024 | benzinga.comPreview: Chimerix's EarningsFebruary 28, 2024 | markets.businessinsider.comChimerix is about to announce its earnings — here's what Wall Street expectsFebruary 27, 2024 | finance.yahoo.comChimerix to Present at TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | finance.yahoo.comChimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024February 22, 2024 | globenewswire.comChimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024February 18, 2024 | finance.yahoo.comChimerix, Inc. (NASDAQ:CMRX) surges 24%; individual investors who own 43% shares profited along with institutionsJanuary 9, 2024 | msn.comLightning Could Strike Twice for Biotech Penny Stock Chimerix (NASDAQ:CMRX)December 29, 2023 | finance.yahoo.comChimerix Appoints Lisa Decker to Board of DirectorsDecember 14, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Chimerix StockDecember 4, 2023 | marketwatch.comChimerix Names Michelle LaSpaluto to Chief Financial OfficerSee More Headlines Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/26/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMRX CUSIPN/A CIK1117480 Webwww.chimerix.com Phone(919) 806-1074Fax919-806-1146Employees72Year Founded2000Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+788.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,100,000.00 Net Margins-25,337.96% Pretax Margin-25,337.96% Return on Equity-37.93% Return on Assets-35.02% Debt Debt-to-Equity RatioN/A Current Ratio10.25 Quick Ratio10.25 Sales & Book Value Annual Sales$320,000.00 Price / Sales250.90 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book0.41Miscellaneous Outstanding Shares89,210,000Free Float80,289,000Market Cap$80.29 million OptionableOptionable Beta1.15 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael T. Andriole M.B.A. (Age 51)CEO, President & Director Comp: $592.95kDr. Allen S. Melemed M.B.A. (Age 60)M.D., Chief Medical Officer Comp: $605.29kMs. Michelle LaSpaluto (Age 49)Chief Financial Officer Mr. Thomas J. Riga (Age 48)Chief Operating & Commercial Officer Mr. David Jakeman CPA (Age 46)VP of Accounting & Finance Dr. Joshua E. Allen Ph.D.Chief Technology OfficerDr. Michael A. Alrutz J.D. (Age 54)Ph.D., Senior VP, General Counsel & Corporate Secretary Comp: $619.5kDr. Roy W. Ware MBAPh.D., Chief Manufacturing Technology OfficerDr. Pablo Lee M.D.Head of Medical AffairsMore ExecutivesKey CompetitorsLifeVantageNASDAQ:LFVNQ32 BioNASDAQ:QTTBLeap TherapeuticsNASDAQ:LPTXAffimedNASDAQ:AFMDEton PharmaceuticalsNASDAQ:ETONView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 44,923 shares on 4/24/2024Ownership: 0.509%Vestal Point Capital LPBought 1,400,000 shares on 2/14/2024Ownership: 1.575%Michael T AndrioleSold 1,744 sharesTotal: $1,813.76 ($1.04/share)Pale Fire Capital SEBought 112,318 shares on 2/14/2024Ownership: 0.238%David JakemanSold 2,660 sharesTotal: $2,766.40 ($1.04/share)View All Insider TransactionsView All Institutional Transactions CMRX Stock Analysis - Frequently Asked Questions Should I buy or sell Chimerix stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMRX shares. View CMRX analyst ratings or view top-rated stocks. What is Chimerix's stock price target for 2024? 3 analysts have issued 1-year target prices for Chimerix's shares. Their CMRX share price targets range from $6.00 to $11.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 789.0% from the stock's current price. View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts. How have CMRX shares performed in 2024? Chimerix's stock was trading at $0.9625 on January 1st, 2024. Since then, CMRX shares have decreased by 6.5% and is now trading at $0.8999. View the best growth stocks for 2024 here. Are investors shorting Chimerix? Chimerix saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,320,000 shares, an increase of 6.5% from the March 31st total of 1,240,000 shares. Based on an average daily volume of 419,700 shares, the short-interest ratio is presently 3.1 days. Currently, 1.7% of the shares of the company are sold short. View Chimerix's Short Interest. When is Chimerix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our CMRX earnings forecast. How can I listen to Chimerix's earnings call? Chimerix will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Chimerix's earnings last quarter? Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. Chimerix had a negative trailing twelve-month return on equity of 37.93% and a negative net margin of 25,337.96%. What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD). Who are Chimerix's major shareholders? Chimerix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.51%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole, Michelle Laspaluto and Robert J Meyer. View institutional ownership trends. How do I buy shares of Chimerix? Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMRX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
